2.65
0.13 (5.16%)
| Penutupan Terdahulu | 2.52 |
| Buka | 2.53 |
| Jumlah Dagangan | 3,851,994 |
| Purata Dagangan (3B) | 5,381,587 |
| Modal Pasaran | 417,491,616 |
| Harga / Pendapatan (P/E TTM) | 5.52 |
| Harga / Pendapatan (P/E Ke hadapan) | 1.07 |
| Harga / Jualan (P/S) | 1.45 |
| Harga / Buku (P/B) | 7.99 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
| Margin Keuntungan | 23.08% |
| Margin Operasi (TTM) | 46.41% |
| EPS Cair (TTM) | 0.380 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 43.20% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 2,155.20% |
| Nisbah Semasa (MRQ) | 1.25 |
| Aliran Tunai Operasi (OCF TTM) | -86.23 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -44.20 M |
| Pulangan Atas Aset (ROA TTM) | 9.69% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | CytomX Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | -0.38 |
|
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.15% |
| % Dimiliki oleh Institusi | 57.78% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Laurion Capital Management Lp | 31 Mar 2025 | 1,293,686 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 5.00 (HC Wainwright & Co., 88.68%) | Beli |
| 5.00 (Piper Sandler, 88.68%) | Beli | |
| Median | 5.00 (88.68%) | |
| Purata | 5.00 (88.68%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 2.03 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 May 2025 | 5.00 (88.68%) | Beli | 2.06 |
| 15 May 2025 | 5.00 (88.68%) | Beli | 2.00 | |
| Piper Sandler | 15 May 2025 | 5.00 (88.68%) | Beli | 2.00 |
| 14 Apr 2025 | 2.50 (-5.66%) | Beli | 0.606 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |